Navigation Links
Pediatric Academic Societies' Annual Meeting to Feature Data,Presentations Related to MedImmune Clinical Programs in Influenza,,RSV and hMPV

GAITHERSBURG, Md., May 2 /PRNewswire-FirstCall/ -- MedImmune, Inc. (Nasdaq: MEDI) today announced that seven abstracts will be presented at the 2007 Pediatric Academic Societies' (PAS) Annual Meeting demonstrating the company's commitment to advancing the science of pediatric medicine. Data are from studies pertaining to MedImmune's approved and development-stage products, including both monoclonal antibodies and vaccines targeting respiratory infectious diseases such as influenza, respiratory syncytial virus (RSV) and human metapneumovirus (hMPV).

"MedImmune is dedicated to advancing research on the prevention and treatment of infectious diseases that put children at risk," said Edward M. Connor, M.D., executive vice president and chief medical officer. "We are committed to improving children's health both with our currently marketed products and through the potential of our robust infectious disease pipeline."

During the PAS meeting, which occurs from May 5 to 8, 2007 in Toronto, Canada, MedImmune will award several pediatric research grants through the company's annual pediatric fellowship program, which is designed to stimulate increased interest and research in the area of respiratory pathogens. Over the last 3 years, MedImmune has awarded pediatric research grants totaling nearly $700,000. In addition, MedImmune currently supports two other research grants through the Pediatric Infectious Disease Society, which will also be awarded in conjunction with the PAS annual meeting.

Data pertaining to MedImmune infectious disease programs that will be presented during the meeting include:

    Influenza
    -- School-Based Influenza Vaccination of Elementary Students Reduced
       Countywide School Absenteeism (Platform Presentation) -- M. Davis et
       al, Saturday, May 5, 2007 from 4:45 p.m.-5:00 p.m. Eastern Time (ET),
       Metro Toronto Convention Centre, Room 206F
    -- Economic 
and Social Benefits of a School-Based Influenza Immunization
       Program (Poster Presentation) -- S. Li et al, Sunday, May 6, 2007 from
       11:00 a.m. to 3:00 p.m. ET, Metro Toronto Convention Centre, Exhibit
       Hall E
    -- Post Marketing Evaluation of the Safety of LAIV (Poster Presentation)-
       R. Baxter et al, Sunday, May 6, 2007 from 11:00 a.m. to 3:00 p.m. ET,
       Metro Toronto Convention Centre, Exhibit Hall E
    -- Cost-Effectiveness of Cold-Adapted Influenza Vaccine, Trivalent (CAIV-
       T) in Preventing Influenza in Young Children Attending Daycare Centers
       (Poster Presentation) -- K. McLaurin et al, Tuesday, May 8, 2007 from
       10:00 a.m. to 2:00 p.m. ET, Metro Toronto Convention Centre, Exhibit
       Hall E
    -- Prevention of the Influenza B Outbreak During the 2005-06 Influenza
       Season Through a Universal Vaccination Program in Children (Platform
       Presentation) -- P. Piedra et al, Tuesday, May 8, 2007 from 2:00 p.m.-
       2:15 p.m. ET, Metro Toronto Convention Centre, Room 701B

    RSV
    -- Phase 3 Trial of Motavizumab, an Enhanced Potency RSV Specific Mab for
       the Prevention of Serious RSV Disease in High-Risk Infants (Poster
       Presentation) -- X. Carbonell et al, Tuesday, May 8, 2007 from 10:15
       a.m. to 12:15 p.m. ET, Metro Toronto Convention Centre, Room 801B

    hMPV
    -- Prevalence and Characteristics of Human Metapneumovirus (hMPV)
       Infection Among Hospitalized Children at High Risk for Severe Lower
       Respiratory Illnesses (LRI) (Platform Presentation) -- R. Yogev et al,
       Sunday, May 6, 2007 from 4:15 p.m. to 4:30 p.m. ET, Metro Toronto
       Convention Centre, Room 707

Additional information regarding the Pediatric Academic Societies' Annual Meeting can be found at http://www.pas-meeting.org/2007Toronto/default.htm.

About MedImmune

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at www.medimmune.com.

Forward Looking Statements

This announcement contains, in addition to historical information, certain "forward-looking statements" regarding the potential prospects of and the results of clinical trials for MedImmune's infectious disease marketed and pipeline products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change current expectations and could cause actual outcomes and results to differ materially from current expectations. In addition to risks and uncertainties discussed in MedImmune's filings with the U.S. Securities and Exchange Commission, no assurance exists that these product candidates will receive required regulatory approval or that, even if regulatory approval is received, these product candidates will be commercially successful. MedImmune undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise except as may be required by applicable law or regulation.

Notice to Investors and Stockholders of MedImmune

This release is neither an offer to purchase nor a solicitation of an offer to sell shares of MedImmune. MedImmune stockholders are urged to read the relevant tender offer documents from AstraZeneca PLC when such become available because they will contain important information that stockholders should consider before making any decision regarding tendering their shares. At the time the offer is commenced, AstraZeneca will file tender offer materials with the U .S. Securities and Exchange Commission, and MedImmune will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement will contain important information, which should be read carefully before any decision is made with respect to the tender offer. The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be made available for free at the U.S. Securities and Exchange Commission's web site at www.sec.gov, at AstraZeneca's website at www.astrazeneca.com or at MedImmune's website at www.medimmune.com.

SOURCE  MedImmune, Inc.
    -0-                             05/02/2007
    /CONTACT:  media, Karen Lancaster, +1-301-398-5864, or investors, Beatrice
Pierre, +1-301-398-4905, both of MedImmune, Inc./
    /Web site:  http://www.medimmune.com
                http://www.astrazeneca.com /
    (MEDI)

CO:  MedImmune, Inc.
ST:  Maryland, Ontario
IN:  IDC HEA MTC
SU:  TRI SVY TDS CHI

AR-MT
-- NEW050 --
0241 05/02/2007 08:15 EDT http://www.prnewswire.com

'"/>




Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants
3. Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer
4. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
5. New Studies Evaluating NexiumIn Pediatric GERD To Be Presented At Annual Digestive Disease Week Meeting
6. Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric Academic Societies Annual Meeting
7. Research Results on FluMist Presented at National Association of Pediatric Nurse Practitioners Conference
8. Replidyne Phase II Pediatric Trial Meets Primary Objective
9. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
10. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
11. Micromet, Inc. to Present at the 3rd Annual C.E. Unterberg, Towbin Emerging Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  A recent study at ... four freestanding hospitals in the country dedicated to the ... reconstructive surgery, concluded that the Surfacide Helios ® ... component in reducing bacterial pathogens not killed by the ... published at the American Burn Association,s 49th Annual Meeting ...
(Date:3/27/2017)... 2017  Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... shares of common stock in an underwritten public offering ... the Securities and Exchange Commission (the "SEC"). The offering ... can be no assurance as to whether or when ... actual size or terms of the offering. Cryoport also ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
Breaking Medicine Technology:
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Public relations ... and across a variety of business channels. , While many results are clear, much ... public relations program. , When it comes to measurement, firms should always take ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/28/2017)... ... 2017 , ... Bacteria and fungi are probably not the first ingredients that come to mind ... right microorganisms in your diet can actually improve health outcomes. And the good news is ... topic of a new peer-reviewed paper led by Maria Marco, Ph.D. , ...
(Date:3/27/2017)... Ohio (PRWEB) , ... March 27, 2017 , ... New ... OH to replace their missing teeth can now have them placed by Dr. Manju ... the latest i-CAT® Cone Beam technology to increase the accuracy of each dental implant ...
(Date:3/27/2017)... ... ... A study by the founder of the Buckingham Center for Facial Plastic ... published in the American Journal of Cosmetic Surgery. “The Effects of an Antistick Phospholipid ... the use of Electro Lube during the facelift procedure. The journal, a publication of ...
Breaking Medicine News(10 mins):